Get the Stockscreener App
3.83
4.25%
-0.17
After Hours:
3.84
0.010
+0.26%
Larimar Therapeutics Inc stock is traded at $3.83, with a volume of 1.74M.
It is down -4.25% in the last 24 hours and up +4.64% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
See More
Previous Close:
$4.00
Open:
$4
24h Volume:
1.74M
Relative Volume:
0.81
Market Cap:
$397.87M
Revenue:
-
Net Income/Loss:
$-166.01M
P/E Ratio:
-1.8433
EPS:
-2.0778
Net Cash Flow:
$-131.32M
1W Performance:
+0.00%
1M Performance:
+4.64%
6M Performance:
+4.36%
1Y Performance:
-1.29%
1-Day Range:
$3.805
$4.06
1-Week Range:
$3.74
$4.17
52-Week Range:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.83 | 415.53M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LRMR|Larimar Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
TradingKey - TradingKey
Larimar Therapeutics Market Sentiment - Benzinga España
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR - TradingView
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
LRMR|Larimar Therapeutics Inc|Price:4.000|Chg%:-0.010 - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
Larimar Therapeutics Files First Module of BLA for Nomlabofusp in Friedreich's Ataxia TreatmentNew Analyst Coverage - dars.gov.et
Larimar Therapeutics Initiates BLA Submission for Nomlabofusp in Friedreich’s AtaxiaProfit Guidance Range - dars.gov.et
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
Price to sales forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics - Moomoo
Larimar Therapeutics stock jumps on insider purchase By Investing.com - Investing.com South Africa
Larimar Therapeutics stock jumps on insider purchase - Investing.com
Larimar Therapeutics director buys $166,890 in company stock - Investing.com UK
Enterprise value to revenue forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 - TradingView
Larimar Therapeutics director buys $166,890 in company stock By Investing.com - Investing.com South Africa
Form 4 Larimar Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Larimar Therapeutics (LRMR) director purchases 50,000 common shares - Stock Titan
Law firm probes Larimar Therapeutics for possib... - Pluang
Larimar Starts FDA Filing for FA Drug With Mid-2027 Goal - MyChesCo
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Here’s What Citi Thinks About Larimar Therapeutics (LRMR) - Insider Monkey
H.C. Wainwright initiates Larimar stock coverage with buy rating - Investing.com UK
LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Larimar stock coverage with buy rating By Investing.com - Investing.com South Africa
Larimar Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy - Moomoo
Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
H.C. Wainwright Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $10 - Moomoo
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk - Moomoo
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's AtaxiaSlideshow (NASDAQ:LRMR) 2026-07-01 - Seeking Alpha
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Moomoo
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
LRMR Maintains by Baird -- Price Target Lowered to $5.00 - GuruFocus
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):